38 results on '"Mitsikostas, Dimos D."'
Search Results
2. Implications of Placebos and Nocebos in Clinical Practice
- Author
-
Mitsikostas, Dimos D., Martelletti, Paolo, Series Editor, Mitsikostas, Dimos D., editor, and Benedetti, Fabrizio, editor
- Published
- 2019
- Full Text
- View/download PDF
3. Onabotulinumtoxina in the Prevention of Migraine in Pediatric Population: A Systematic Review.
- Author
-
Mavridi, Artemis, Redmond, Aine, Archontakis-Barakakis, Paraschos, Bogdanova-Mihaylova, Petya, Deligianni, Christina I., Mitsikostas, Dimos D., and Mavridis, Theodoros
- Subjects
BOTULINUM A toxins ,PEDIATRIC therapy ,MIGRAINE ,CLEARCUTTING ,TEENAGERS ,CHILD patients - Abstract
Migraine is a leading cause of disability worldwide, yet it remains underrecognized and undertreated, especially in the pediatric and adolescent population. Chronic migraine occurs approximately in 1% of children and adolescents requiring preventive treatment. Topiramate is the only FDA-approved preventative treatment for children older than 12 years of age, but there is conflicting evidence regarding its efficacy. OnabotulinumtoxinA is a known and approved treatment for the management of chronic migraine in people older than 18 years. Several studies examine its role in the pediatric population with positive results; however, the clear-cut benefit is still unclear. OnabotulinumtoxinA seems not only to improve disability scores (PedMIDAS) but also to improve the quality, characteristics, and frequency of migraines in the said population. This systematic review aims to summarize the evidence on the efficacy, dosing, administration, long-term outcomes, and safety of onabotulinumtoxinA in pediatric and adolescent migraine. Eighteen studies met the eligibility criteria and were included in this review. The mean monthly migraine days (MMDs), decreased from of 21.2 days per month to 10.7 after treatment. The reported treatment-related adverse effects were mild and primarily injection site related and ranged from 0% to 47.0%. Thus, this review provides compelling evidence suggesting that OnabotulinumtoxinA may represent a safe and effective preventive treatment option for pediatric migraine. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. New players in the preventive treatment of migraine
- Author
-
Mitsikostas, Dimos D and Rapoport, Alan M
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Prevention ,Neurosciences ,Clinical Research ,Headaches ,Clinical Trials and Supportive Activities ,Migraines ,Pain Research ,Chronic Pain ,Brain Disorders ,Adult ,Antibodies ,Monoclonal ,Female ,Humans ,Male ,Migraine Disorders ,Vagus Nerve Stimulation ,Migraine ,Cluster headache ,CGRP ,Monoclonal antibodies ,Neurostimulation ,Neuromodulation ,Vagus nerve stimulation ,Supraorbital and supratrochlear nerve stimulation ,Medical and Health Sciences ,General & Internal Medicine ,Biomedical and clinical sciences ,Health sciences - Abstract
Migraine is a common, chronic disorder of the brain causing much disability, as well as personal, familial and societal impact. Several oral preventive agents are available in different countries for the prevention of migraine, but none have performed better than 50% improvement in 50% of patients in a clinical trial. Additionally, each has various possible adverse events making their tolerability less than optimal. Recently, three monoclonal antibodies targeting the calcitonin gene-related peptide (CGRP) ligand (LY2951742, ALD403 and TEV-48125) and one targeting the CGRP receptor (AMG 334) have completed phase 2 trials, and the results have been reported. These early results show them all to be somewhat more effective than placebo, with no serious adverse events. Three have been studied for episodic migraine, and only TEV-48125 has been studied for both high frequency episodic and chronic migraine. Moreover, preliminary data suggests that neurostimulation is effective in migraine treatment, including stimulation of the sphenopalatine ganglion, transcutaneous supraorbital and supratrochlear nerve, and transcutaneous vagus nerve. In this article, these innovative therapies will be reviewed.
- Published
- 2015
5. Placebo and Nocebo Effects
- Author
-
Mitsikostas, Dimos D., Deligianni, Christina I., Martelletti, Paolo, Series editor, Jensen, Rigmor, Series editor, Mitsikostas, Dimos D., editor, and Paemeleire, Koen, editor
- Published
- 2016
- Full Text
- View/download PDF
6. Depression and Anxiety Symptoms in Headache Disorders: An Observational, Cross-Sectional Study.
- Author
-
Mantonakis, Leonidas, Belesioti, Ioanna, Deligianni, Christina I., Natsis, Vasilis, Mitropoulou, Euthimia, Kasioti, Elina, Lypiridou, Maria, and Mitsikostas, Dimos D.
- Subjects
MENTAL depression ,HEADACHE ,MEDICATION overuse headache ,MEDICATION abuse ,CLUSTER headache ,EPISODIC memory - Abstract
Background: Headache disorders have been associated with anxiety and depressive disorders. The aim of this study was to assess symptoms of anxiety and depression in a large sample of individuals with different headache disorders (HDs) in order to determine whether their frequency differs by headache type. Methods: Consecutive individuals with headache attending a headache outpatient clinic were interviewed with the HAM-D and HAM-A, along with age, sex, and education matched non-headache individuals. Results: Individuals numbering 2673 with headache (females 71.2%) and 464 non-headache individuals (females 70.9%) were interviewed (with participation rates of 98.3% and 91.0%, respectively). Migraine was diagnosed in 49.7%, tension-type headache in 38%, cluster headache 5.2%, and medication overuse (MO) in 21.8%. Participants with HD scored more in HAM-A (OR = 4.741, CI95%: 3.855–5.831, p < 0.001) and HAM-D scales (OR = 2.319, CI95%: 1.892–2.842, p < 0.001) than non-headache individuals. Participants with chronic HDs (≥15 days with headache for ≥3 consecutive months; 52.5%) scored higher for both HAM-A (OR = 1.944, CI95%: 1.640–2.303, p < 0.001) and HAM-D (OR = 1.625, CI95%: 1.359–1.944, p < 0.001) than those with episodic HDs (33.1%), as did participants with MO vs. participants without MO (OR = 3.418, CI95%: 2.655–4.399, p < 0.001 for HAM-A, OR = 3.043, CI95%: 2.322–3.986, p < 0.001 for HAM-D). Female and low-educated participants scored higher on both scales. Conclusion: Because symptoms of anxiety and depression are substantial in people with HD, the treating physicians should look out for such symptoms and manage them appropriately. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
7. Responder rates with eptinezumab over 24 weeks in patients with prior preventive migraine treatment failures: post hoc analysis of the DELIVER randomized clinical trial.
- Author
-
Ashina, Messoud, Lipton, Richard B., Ailani, Jessica, Versijpt, Jan, Sacco, Simona, Mitsikostas, Dimos D., Christoffersen, Cecilie Laurberg, Sperling, Bjørn, and Ettrup, Anders
- Subjects
CLINICAL trials ,TREATMENT failure ,MIGRAINE ,NEURAL stimulation - Abstract
Background and purpose: Eptinezumab reduced monthly migraine days more than placebo in the DELIVER study, a clinical trial with patients with difficult‐to‐treat migraine and prior preventive treatment failures. This post hoc analysis assesses the sustained response to eptinezumab at the population and patient level and evaluates the potential for response in initial non‐responders. Methods: Adults with chronic or episodic migraine and two to four prior preventive treatment failures were randomized to eptinezumab 100 mg, 300 mg or placebo every 12 weeks. Primary outcomes in this post hoc analysis are the proportion of patients with ≥30%, ≥50% or ≥75% reduction in monthly migraine days (i.e., migraine responder rates [MRRs]) during weeks 1–12 and weeks 13–24 and across 4‐week intervals. Secondary outcomes are maintenance and shifts in MRRs from weeks 1–12 to weeks 13–24. Results: Between weeks 1–12 and 13–24, ≥30% MRRs increased from 65.9% to 70.4% (100 mg) and from 71.0% to 74.5% (300 mg), versus 36.9% to 43.1% (placebo). The ≥50% and ≥75% MRRs were sustained or increased over the 24‐week period. The largest increase in ≥30% MRRs occurred after the second infusion with eptinezumab. The percentage of initial non‐responders (<30% MRRs during weeks 1–12) who experienced response (≥30% MRRs during weeks 13–24) to the second dose was 34.7% (100 mg) and 30.4% (300 mg) with eptinezumab versus 21.1% with placebo. Conclusion: Across MRR thresholds, most patients who responded to eptinezumab during weeks 1–12 maintained or improved response during weeks 13–24. More than one‐third of initial non‐responders became responders after their second infusion. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
8. Triptans attenuate capsaicin-induced CREB phosphorylation within the trigeminal nucleus caudalis: a mechanism to prevent central sensitization?
- Author
-
Mitsikostas, Dimos D, Knight, Yolande E, Lasalandra, Michele, Kavantzas, Nikolaos, and Goadsby, Peter J
- Subjects
Biomedical and Clinical Sciences ,Neurosciences ,Clinical Sciences ,Headaches ,Migraines ,Chronic Pain ,Pain Research ,Dental/Oral and Craniofacial Disease ,Neurodegenerative ,Neurological ,Animals ,Capsaicin ,Cyclic AMP Response Element-Binding Protein ,Hyperalgesia ,Immunohistochemistry ,Male ,Pain ,Phosphorylation ,Piperidines ,Rats ,Rats ,Sprague-Dawley ,Sensory System Agents ,Sumatriptan ,Trigeminal Caudal Nucleus ,Tryptamines ,CREB ,Naratriptan ,Migraine ,Sensitization ,Genetics ,Neurology & Neurosurgery ,Clinical sciences - Abstract
The c-AMP-responsive element binding protein (CREB) and its phosphorylated product (P-CREB) are nuclear proteins expressed after stimulation of pain-producing areas of the spinal cord. There is evidence indicating that central sensitization within dorsal horn neurons is dependent on P-CREB transcriptional regulation. The objectives of the study were to investigate the expression of P-CREB in cells in rat trigeminal nucleus caudalis after noxious stimulation and to determine whether pre-treatment with specific anti-migraine agents modulate this expression. CREB and P-CREB labelling was investigated within the trigeminal caudalis by immunohistochemistry after capsaicin stimulation. Subsequently, the effect of i.v. pre-treatment with either sumatriptan (n = 5), or naratriptan (n = 7) on P-CREB expression was studied. Five animals pre-treated with i.v. normal saline were served as controls. CREB and P-CREB labelling was robust in all animal groups within Sp5C. Both naratriptan and sumatriptan decreased P-CREB expression (p = 0.0003 and 0.0013) within the Sp5C. Triptans attenuate activation of CREB within the central parts of the trigeminal system, thereby leading to potential inhibition of central sensitization. P-CREB may serve as a new marker for post-synaptic neuronal activation within Sp5C in animal models relevant to migraine.
- Published
- 2011
9. Real-world effectiveness of fremanezumab for the preventive treatment of migraine: Interim analysis of the pan-European, prospective, observational, phase 4 PEARL study.
- Author
-
Ashina, Messoud, Mitsikostas, Dimos D., Amin, Faisal Mohammad, Kokturk, Pinar, Schankin, Christoph J., Sahin, Gurdal, Pozo-Rosich, Patricia, Dorman, Paul J., Nežádal, Tomáš, Poole, Anne Christine, Martins, Isabel Pavão, Sumelahti, Marja-Liisa, Ramirez Campos, Verena, Ahn, Andrew H., Lyras, Leonidas, and Tassorelli, Cristina
- Subjects
- *
MIGRAINE , *CALCITONIN gene-related peptide - Abstract
Background: The ongoing Pan-European Real Life (PEARL) phase 4 study is evaluating fremanezumab effectiveness and safety for the prevention of episodic and chronic migraine. This interim analysis reports primary, secondary and exploratory endpoints from when 500 participants completed at least six months of treatment. Methods: Adults with episodic migraine or chronic migraine maintaining daily headache diaries were enrolled upon initiation of fremanezumab. Primary endpoint: proportion of participants with ≥50% reduction in monthly migraine days during the six-month period after fremanezumab initiation. Secondary endpoints: mean change from baseline across months 1–12 in monthly migraine days, acute migraine medication use, and headache-related disability. Exploratory endpoint: mean change in headache severity from baseline across months 1–12. Safety was assessed through adverse events reported. Results: Overall, 897 participants were enrolled and 574 included in the effectiveness analyses (episodic migraine, 25.8%; chronic migraine, 74.2%). Of participants with data available, 175/313 (55.9%) achieved ≥50% monthly migraine days reduction during the six-month period post-initiation. Across months 1–12, there were sustained reductions in mean monthly migraine days, acute medication use, disability scores, and headache severity. Few adverse events were reported. Conclusion: PEARL interim results support the effectiveness and safety of fremanezumab for migraine prevention in a real-world population across several European countries. Trial registration: encepp.eu: EUPAS35111 [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
10. Numbers needed to treat or harm and likelihood of being helped versus harmed for fremanezumab in patients who had prior inadequate response to two to four classes of migraine preventive medications: A post hoc analysis.
- Author
-
Ashina, Messoud, Mitsikostas, Dimos D., Ramirez Campos, Verena, Barash, Steve, Ning, Xiaoping, and Diener, Hans‐Christoph
- Subjects
- *
MIGRAINE prevention , *THERAPEUTIC use of monoclonal antibodies , *STATISTICS , *MIGRAINE , *NEUROPEPTIDES , *CALCITONIN , *TREATMENT effectiveness , *RANDOMIZED controlled trials , *BLIND experiment , *DESCRIPTIVE statistics , *RESEARCH funding , *DATA analysis , *STATISTICAL sampling , *CHEMICAL inhibitors , *EVALUATION - Abstract
Objective: This study aimed to determine the number needed to treat (NNT), number needed to harm (NNH), and likelihood of being helped or harmed (LHH) in a post hoc analysis of the phase 3b FOCUS trial. Background: Fremanezumab, a humanized monoclonal antibody that selectively targets calcitonin gene–related peptide (CGRP), has demonstrated efficacy, tolerability, and safety in adults with episodic migraine (EM) or chronic migraine (CM), with documented previous inadequate response to two to four classes of migraine preventive medications. Methods: In the 12‐week double‐blind period of the FOCUS study, patients were randomized (1:1:1) to quarterly fremanezumab, monthly fremanezumab, or matched monthly placebo. NNT was based on responder analysis, defined as ≥50% reduction in monthly average number of migraine days at 12 weeks. NNH was based on discontinuations due to adverse events (AEs). Results: Among patients with CM (n = 509), response rates and discontinuation rates were 27% (45/169) and 0 for quarterly fremanezumab, 29% (50/173) and 2% (3/173) for monthly fremanezumab, and 8% (13/167) and <1% (1/167) for placebo, respectively. These results translated to NNTs of 5.3 and 4.7, NNHs of 1000 and 88, and LHHs of 188 and 19 for quarterly and monthly fremanezumab, respectively. Among patients with EM (n = 328), response rates were 47% (50/107) for quarterly fremanezumab, 43% (47/110) for monthly fremanezumab, and 10% (11/111) for placebo. Discontinuation rates were <1% (n = 1) in all three groups. These results translated to NNTs of 2.7 and 3.0, NNHs of 1000 and 1000, and LHHs of 368 and 328 for quarterly and monthly fremanezumab, respectively. Conclusions: The NNT, NNH, and LHH for quarterly and monthly fremanezumab compare favorably with those for traditional oral preventive medications, including topiramate, valproate, and propranolol. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
11. The 5-HT1F receptor as the target of ditans in migraine — from bench to bedside.
- Author
-
Mitsikostas, Dimos D., Waeber, Christian, Sanchez-del-Rio, Margarita, Raffaelli, Bianca, Ashina, Håkan, Maassen van den Brink, Antoinette, Andreou, Anna, Pozo-Rosich, Patricia, Rapoport, Alan, Ashina, Messoud, and Moskowitz, Michael A.
- Subjects
- *
SEROTONIN agonists , *CALCITONIN gene-related peptide , *MIGRAINE , *VASCULAR smooth muscle , *SEROTONIN syndrome , *PATIENT compliance - Abstract
Migraine is a leading cause of disability in more than one billion people worldwide, yet it remains universally underappreciated, even by individuals with the condition. Among other shortcomings, current treatments (often repurposed agents) have limited efficacy and potential adverse effects, leading to low treatment adherence. After the introduction of agents that target the calcitonin gene-related peptide pathway, another new drug class, the ditans — a group of selective serotonin 5-HT1F receptor agonists — has just reached the international market. Here, we review preclinical studies from the late 1990s and more recent clinical research that contributed to the development of the ditans and led to their approval for acute migraine treatment by the US Food and Drug Administration and the European Medicines Agency. Ditans are a recently developed drug class for the treatment of acute migraine. In this Review, the authors provide an overview of ditan development, from the initial rationale to the clinical studies that led to the recent FDA approval of the first ditan. Key points: Various animal studies have shown that selective agonists for the serotonin 5-HT1F receptor can reduce signals from an activated trigeminovascular system, thereby highlighting the receptor as an attractive target for symptomatic treatment of migraine. Long-term clinical studies involving two ditans — a group of 5-HT1F agonists — have provided class I evidence that lasmiditan, the first ditan, is both effective and safe in the symptomatic treatment of migraine. The 5-HT1F receptor is expressed by cells within the brain parenchyma, as well as by the trigeminal neurons, but not in vascular smooth muscle, suggesting that ditans act through neuropeptide release leading to acute headache relief, rather than via potential vasoactive properties, such as vasodilatation. Dizziness is the most common adverse event of lasmiditan; thus people should not drive for 8 h after taking lasmiditan. Development of novel ditans that do not cross the blood–brain barrier is expected to result in better tolerability and improved clinical use. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
12. Male and female sex hormones in primary headaches
- Author
-
Delaruelle, Zoë, Ivanova, Tatiana A., Khan, Sabrina, Negro, Andrea, Ornello, Raffaele, Raffaelli, Bianca, Terrin, Alberto, Mitsikostas, Dimos D., Reuter, Uwe, and on behalf of the European Headache Federation School of Advanced Studies (EHF-SAS)
- Published
- 2018
- Full Text
- View/download PDF
13. Onabotulinumtoxin-A treatment in Greek patients with chronic migraine
- Author
-
Vikelis, Michail, Argyriou, Andreas A., Dermitzakis, Emmanouil V., Spingos, Konstantinos C., and Mitsikostas, Dimos D.
- Published
- 2016
- Full Text
- View/download PDF
14. Structured Q1 headache services as the solution to the ill-health burden of headache:1. Rationale and description
- Author
-
Steiner, Timothy J., Jensen, Rigmor, Katsarava, Zaza, Stovner, Lars Jacob, Uluduz, Derya, Adarmouch, Latifa, Al Jumah, Mohammed, Al Khathaami, Ali M., Ashina, Messoud, Braschinsky, Mark, Broner, Susan, Eliasson, Jon H., Gil-Gouveia, Raquel, Gómez-Galván, Juan B., Gudmundsson, Larus S., Herekar, Akbar A., Kawatu, Nfwama, Kissani, Najib, Kulkarni, Girish Baburao, Lebedeva, Elena R., Leonardi, Matilde, Linde, Mattias, Luvsannorov, Otgonbayar, Maiga, Youssoufa, Milanov, Ivan, Mitsikostas, Dimos D., Musayev, Teymur, Olesen, Jes, Osipova, Vera, Paemeleire, Koen, Peres, Mario F. P., Quispe, Guiovanna, Rao, Girish N., Risal, Ajay, de la Torre, Elena Ruiz, Saylor, Deanna, Togha, Mansoureh, Yu, Sheng-Yuan, Zebenigus, Mehila, Zewde, Yared Zenebe, Zidverc-Trajković, Jasna, and Tinelli, Michela
- Subjects
services ,Medizin ,UNITED-STATES ,UTILIZATION ,DISEASE ,TENSION-TYPE HEADACHE ,Headache disorders ,Medicine and Health Sciences ,SYSTEMATIC ANALYSIS ,NATIONAL BURDEN ,Public health ,Global Campaign against headache ,Health-technology assessment ,DISABILITY ,Global ,GLOBAL BURDEN ,CARE ,Primary care ,Health policy ,PREVALENCE ,Campaign against headache ,Needs assessment ,MIGRAINE ,Barriers to care ,Service organization and delivery ,Structured headache services ,Structured headache - Abstract
In countries where headache services exist at all, their focus is usually on specialist (tertiary) care. This is clinically and economically inappropriate: most headache disorders can effectively and more efficiently (and at lower cost) be treated in educationally supported primary care. At the same time, compartmentalizing divisions between primary, secondary and tertiary care in many health-care systems create multiple inefficiencies, confronting patients attempting to navigate these levels (the “patient journey”) with perplexing obstacles. High demand for headache care, estimated here in a needs-assessment exercise, is the biggest of the challenges to reform. It is also the principal reason why reform is necessary. The structured headache services model presented here by experts from all world regions on behalf of the Global Campaign against Headache is the suggested health-care solution to headache. It develops and refines previous proposals, responding to the challenge of high demand by basing headache services in primary care, with two supporting arguments. First, only primary care can deliver headache services equitably to the large numbers of people needing it. Second, with educational supports, they can do so effectively to most of these people. The model calls for vertical integration between care levels (primary, secondary and tertiary), and protection of the more advanced levels for the minority of patients who need them. At the same time, it is amenable to horizontal integration with other care services. It is adaptable according to the broader national or regional health services in which headache services should be embedded. It is, according to evidence and argument presented, an efficient and cost-effective model, but these are claims to be tested in formal economic analyses. CA extern
- Published
- 2021
15. Nocebo in Headaches: Implications for Clinical Practice and Trial Design
- Author
-
Mitsikostas, Dimos D.
- Published
- 2012
- Full Text
- View/download PDF
16. Galcanezumab in migraine prevention: a systematic review and meta-analysis of randomized controlled trials.
- Author
-
Gklinos, Panagiotis and Mitsikostas, Dimos D.
- Abstract
Background: Galcanezumab, along with three other monoclonal antibodies targeting the calcitonin gene-related peptide (CGRP) pathway, represents the latest disease-specific and mechanism-based treatment for the prophylaxis of migraine. Galcanezumab shares data also for the prophylaxis of cluster headache. Objective: To provide a pooled safety and efficacy analysis of all phase III randomized controlled trials of galcanezumab in the preventive therapy of migraine. Methods: A computer-based literature search was conducted on MEDLINE and the US National Institutes of Health Clinical Trials Registry for phase III randomized controlled trials of galcanezumab in migraine prevention. The primary outcome was the mean change in monthly migraine days (MMDs). The proportions of patients who reported at least one adverse event (AE), at least one serious adverse event (SAE) or withdrew from the study were used as safety outcomes. Results: Two trials were included in the efficacy meta-analysis and three in the safety meta-analysis. Migraine preventive treatment with subcutaneous galcanezumab, at both 120 mg and 240 mg dosages, was associated with a significantly greater reduction in the mean number of MMDs versus placebo (120 mg, MD = –1.98, 95% CI = –2.33 to –1.63; p < 0.0001) or (240 mg, MD = –1.86, 95% CI = –2.20 to –1.53; p < 0.0001). Galcanezumab was found to be more efficacious in all key secondary outcomes as well. Regarding safety, most of the adverse events were mild to moderate, while drop-out rates and serious adverse events were low. Conclusions: Galcanezumab is an efficacious and well-tolerated preventive treatment for migraine. Larger clinical trials with longer follow-up periods need to be conducted in order to provide more safety data of the above-mentioned drug. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
17. Placebo and nocebo phenomena in anti- CGRP monoclonal antibody trials for migraine prevention: a meta-analysis.
- Author
-
Kokoti, Lili, Drellia, Konstantina, Papadopoulos, Dimitrios, and Mitsikostas, Dimos D.
- Subjects
MONOCLONAL antibodies ,CALCITONIN gene-related peptide ,MIGRAINE ,PLACEBOS ,NOCEBOS ,META-analysis - Abstract
High placebo and low nocebo phenomena mirror high positive expectations for a novel treatment, among other reasons. In a meta-analysis aimed to identify placebo and nocebo phenomena in the placebo-controlled randomized trials (RCTs) with the monoclonal antibodies targeting the calcitonin gene-related peptide pathway (anti-CGRP mAbs) all the placebo-treated patients were pooled and compared with the placebo-treated patients in RCTs with topiramate and onabotulinum toxin A (OBTA). In episodic migraine (EM), the proportion of placebo-treated patients who achieved the 50% responder rate (placebo) was 32.7% (95% CI 28.6%–37.0%) in anti-CGRP mAbs vs. 24.4% (95% CI 20.5%–28.5%) in topiramate trials. The proportion of dropouts due to adverse events in placebo-treated patients (nocebo) was 1.9% (95% CI 1.4%–2.6%) in anti-CGRP mAbs vs. 9.9% (95% CI 7.7%–12.3%) in topiramate RCTs. In chronic migraine (CM), the placebo 50% responder rate was 23.6% (95% CI 11.2%–38.8%) in anti-CGRP mAbs RCTs vs. 36.4% (95% CI 32.6%–39.3%) in RCTs with OBTA. The nocebo dropout in anti-CGRP mAbs and OBTA RCTs was 1.4% (95% CI 0.8%–2.1%) and 0.9 (95% CI 0.3%–1.7%), respectively. The stronger placebo and weaker nocebo phenomena in RCTs with anti-CGRP mAbs vs. those with topiramate in the prophylaxis of EM, may decisively determine anti-CGRP mAbs treatment success. No differences were detected between the anti-CGRP mAbs and OBTA in the treatment of CM. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
18. Consensus of the Hellenic Headache Society on the diagnosis and treatment of migraine.
- Author
-
Kouremenos, Evangelos, Arvaniti, Chrysa, Constantinidis, Theodoros S., Giannouli, Ermioni, Fakas, Nikolaos, Kalamatas, Themistoklis, Kararizou, Evangelia, Naoumis, Dimitrios, and Mitsikostas, Dimos D.
- Subjects
MIGRAINE diagnosis ,MIGRAINE prevention ,ANALGESICS ,BOTULINUM toxin ,CHRONIC diseases ,CONSENSUS (Social sciences) ,HETEROCYCLIC compounds ,MEDICAL protocols ,METOPROLOL ,MIGRAINE ,MONOCLONAL antibodies ,NONSTEROIDAL anti-inflammatory agents ,VALPROIC acid ,TOPIRAMATE ,VENLAFAXINE ,PROPRANOLOL ,HEALTH literacy ,CANDESARTAN - Abstract
More than 0.6 million people suffer from disabling migraines in Greece causing a dramatic work loss, but only a small proportion of migraineurs attend headache centres, most of them being treated by non-experts. On behalf of the Hellenic Headache Society, we report here a consensus on the diagnosis and treatment of adult migraine that is based on the recent guidelines of the European Headache Federation, on the principles of Good Clinical Practice and on the Greek regulatory affairs. The purposes are three-fold: (1) to increase awareness for migraine in Greece; (2) to support Greek practitioners who are treating migraineurs; and (3) to help Greek migraineurs to get the most appropriate treatment. For mild migraine, symptomatic treatment with high dose simple analgesics is suggested, while for moderate to severe migraines triptans or non-steroidal anti-inflammatory drugs, or both, should be administered following an individually tailored therapeutic strategy. A rescue acute treatment option should always be advised. For episodic migraine prevention, metoprolol (50–200 mg/d), propranolol (40–240 mg/d), flunarizine (5–10 mg/d), valproate (500–1800 mg/d), topiramate (25–100 mg/d) and candesartan (16–32 mg/d) are the drugs of first choice. For chronic migraine prevention topiramate (100-200 mg/d), valproate (500–1800 mg/d), flunarizine (5–10 mg/d) and venlafaxine (150 mg/d) may be used, but the evidence is very limited. Botulinum toxin type A and monoclonal antibodies targeting the CGRP pathway (anti-CGRP mAbs) are recommended for patients suffering from chronic migraine (with or without medication overuse) who failed or did not tolerate two previous treatments. Anti-CGRP mAbs are also suggested for patients suffering from high frequency episodic migraine (≥8 migraine days per month and less than 14) who failed or did not tolerate two previous treatments. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
19. Rimegepant for migraine: acute efficacy beyond the USA.
- Author
-
Mitsikostas, Dimos D
- Subjects
- *
MIGRAINE - Published
- 2023
- Full Text
- View/download PDF
20. Trigeminal‐Targeted Treatments in Migraine: Is 60% the Magic Number?
- Author
-
Barbanti, Piero, Egeo, Gabriella, and Mitsikostas, Dimos D.
- Subjects
INTRAVENOUS therapy ,MIGRAINE ,NEUROPEPTIDES ,TRIGEMINAL nerve ,PHENOTYPES ,TREATMENT effectiveness - Abstract
Trigeminal‐targeted treatments (TTTs), the most specific and selective therapeutic migraine approach to date, are effective in approximately 60% of patients regardless of treatment type or mechanism, at least if used alone. Sixty percent is also the proportion of migraineurs who develop migraine‐like episodes following experimental intravenous administration of trigeminal neuropeptides and roughly 60% is the percentage of patients with a unilateral migraine tracing the area of cutaneous distribution of the trigeminal ophthalmic branch. Hence, mechanisms other than the trigeminovascular activation are probably involved in the 40% of migraineurs who do not respond to TTTs. A closer cooperation between clinical and basic neuroscientists is needed to explore migraine models because only a careful appraisal of migraine endophenotypes may help to unravel their underlying multifaceted pathophysiological machinery. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
21. Sumatriptan transdermal iontophoretic patch (NP101-Zelrix™): review of pharmacology, clinical efficacy, and safety in the acute treatment of migraine.
- Author
-
Vikelis, Michail, Mitsikostas, Dimos D., and Rapoport, Alan M.
- Subjects
- *
SUMATRIPTAN , *TRANSDERMAL medication , *HEADACHE treatment , *MIGRAINE , *DRUG efficacy , *CLINICAL trials , *PHARMACOLOGY - Abstract
Migraine is a chronic, painful, and often disabling primary headache disorder, typically presenting with recurrent attacks that may be accompanied by a variety of neurological, gastrointestinal, and autonomic symptoms. Gastrointestinal symptoms in association with migraine including, nausea, vomiting, and gastroparesis, affect a large proportion of migraine sufferers. These symptoms may result in delays or inconsistencies in the absorption of oral treatments. Hence, the necessity for an innovative, non-invasive, parenteral delivery formulation for quick and effective treatment of migraine attacks is evident. Iontophoresis utilizes minimal amounts of electrical potential to support the fast transfer of ionized medication transdermally and into the general circulation. Two pharmacokinetic clinical trials have shown that iontophoretic delivery of sumatriptan through the skin produces quick and reproducible therapeutic plasma concentrations. A randomized, double-blind, multicenter, phase III study demonstrated superior efficacy versus placebo and excellent tolerability, with no triptan-related adverse events. The proportion of patients that were pain-free at 2 h post-treatment was 18% for the sumatriptan patch vs 9% for placebo (P = 0.0092; number needed to treat = 11.1). Upon approval from the Food and Drug Administration and other regulatory authorities, the iontophoretic transdermal delivery of sumatriptan will be a good choice for patients experiencing poor absorption of oral medication often associated with migraine and/or for those with intolerable triptan-related adverse events. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
22. Headache in Systemic Lupus Erythematosus vs Multiple Sclerosis: A Prospective Comparative Study.
- Author
-
Katsiari, Christina G., Vikelis, Michail, Paraskevopoulou, Eleftheria S., Sfikakis, Petros P., and Mitsikostas, Dimos D.
- Subjects
QUALITY of life ,ANALYSIS of variance ,COMPARATIVE studies ,FISHER exact test ,HAMILTON Depression Inventory ,HEADACHE ,HEALTH surveys ,LONGITUDINAL method ,MIGRAINE ,MULTIPLE sclerosis ,PROBABILITY theory ,RESEARCH funding ,SYSTEMIC lupus erythematosus ,T-test (Statistics) ,TENSION headache ,U-statistics ,VISUAL analog scale - Abstract
Objective.- To clarify whether headache, and particularly migraine, belongs to the spectrum of neurologic manifestations of systemic lupus erythematosus (SLE), the archetypal autoimmune disease. Methods.- Consecutive SLE patients were matched 1:1 for age, gender, and level of education with healthy control subjects. A representative subgroup of SLE patients were also matched with patients suffering from multiple sclerosis (MS), a nervous system-specific autoimmune disease. All study participants were assessed for headache present in the previous year. Anxiety, depression, and quality of life were also estimated at baseline. During the following year, all participants were assessed every 3 months using specific headache diaries. Results.- Seventy-two SLE/control pairs and 48 MS patients completed 12 months of follow-up. Prevalence of migraine, with or without aura, was similar between SLE patients (21%), MS patients (23%), and controls (22%), as was the prevalence of frequent tension-type headache. Duration and severity of migraine attacks were milder in SLE patients than controls. Only chronic tension-type headache was significantly more prevalent in SLE patients (12.5%) compared to controls (1.4%). MS patients also presented increased frequency of chronic tension-type headache (8.3%). No associations of any headache type with particular clinical manifestations, autoantibody, or disease activity, either in SLE or MS patient groups, were found. Irrespective of the presence of headache, anxiety symptoms and impaired quality of life were more frequent among SLE than MS patients or controls. Conclusion.- Migraine should be no longer considered a neurologic manifestation of systemic or organ-specific autoimmunity. Increased migraine prevalence in these patients found in previous studies could be due to methodological weaknesses. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
23. Nocebo is the enemy, not placebo. A meta-analysis of reported side effects after placebo treatment in headaches.
- Author
-
Mitsikostas, Dimos D, Mantonakis, Leonidas I, and Chalarakis, Nikolaos G
- Subjects
- *
NOCEBOS , *TREATMENT of cluster headaches , *DRUG side effects , *PLACEBOS , *HEADACHE treatment - Abstract
The aim was to determine the magnitude of the nocebo (adverse effects following placebo administration) in clinical trials for primary headache disorders. We reviewed randomized, placebo-controlled studies for migraine, tension-type headache (TTH), and cluster headache treatments published between 1998 and 2009. The frequency of nocebo was estimated by the percentage of placebo-treated patients reporting at least one adverse side effect. The dropout frequency was estimated by the percentage of placebo-treated patients who discontinued the treatment due to intolerance. In studies of symptomatic treatment for migraine, the nocebo and dropout frequencies were 18.45% and 0.33%, but rose to 42.78% and 4.75% in preventative treatment studies. In trials for prevention of TTH, nocebo and dropout frequencies were 23.99% and 5.44%. For symptomatic treatment of cluster headache, the nocebo frequency was 18.67%. Nocebo is prevalent in clinical trials for primary headaches, particularly in preventive treatment studies. Dropouts due to nocebo effect may confound the interpretation of many clinical trials. [ABSTRACT FROM PUBLISHER]
- Published
- 2011
- Full Text
- View/download PDF
24. Sleep and Headache: The Clinical Relationship.
- Author
-
Mitsikostas, Dimos D., Viskos, Alexandros, and Papadopoulos, Dimitrios
- Subjects
- *
HEADACHE , *SLEEP disorders , *MENTAL depression , *ANXIETY - Abstract
The article presents a review of studies on the link between sleep disorders and headaches. A U.S. study indicated that the adult participants aged 18 years or older who reported severe headaches were significantly more likely to have insomnia, excessive sleepiness, recurrent pain and depression or anxiety symptoms during the preceding 12 months. Another study showed a 2-to-3-fold increase in migraine prevalence in narcoleptic patients, and narcolepsy preceded migraine onset in the study participants.
- Published
- 2010
- Full Text
- View/download PDF
25. The Role of Galcanezumab in Migraine Prevention: Existing Data and Future Directions.
- Author
-
Gklinos, Panagiotis, Mitsikostas, Dimos D., and Berzal-Herranz, Alfredo
- Subjects
- *
CALCITONIN gene-related peptide , *CARDIOVASCULAR diseases risk factors , *SPREADING cortical depression , *MIGRAINE , *CLUSTER headache , *MIGRAINE aura , *QUALITY of life , *MONOCLONAL antibodies - Abstract
Galcanezumab is a humanized monoclonal antibody blocking the calcitonin gene-related peptide (CGRP) pathway by targeting the CGRP. Data from four phase-3 randomized placebo-controlled clinical trials showed that galcanezumab is superior to placebo in reducing migraine headaches, migraine-specific quality of life, and headache-related disability. Most of the adverse events (AEs) were mild to moderate and did not affect trial completion rates significantly. Along with erenumab, fremanezumab, and eptinezumab, galcanezumab forms a novel class of anti-migraine preventative treatments that is disease-specific and mechanism-based, unlike the standard ones. In addition, galcanezumab has also been shown to be effective in cluster headache, though more clinical trials are required. Overall, galcanezumab is a promising emerging treatment in migraine prophylaxis. However, it needs to be tested in larger clinical trials focused on treatment-resistant migraine. Furthermore, its safety profile, especially its potential association with an increased cardiovascular risk, needs to be established through long-term, real-world data. This review aims to give an overview of its pharmacological properties as well as to report and discuss data from clinical trials and its potential place in headache therapeutics. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
26. Monoclonal Antibodies as Neurological Therapeutics.
- Author
-
Gklinos, Panagiotis, Papadopoulou, Miranta, Stanulovic, Vid, Mitsikostas, Dimos D., Papadopoulos, Dimitrios, and Rauter, Amélia Pilar
- Subjects
NEUROMUSCULAR diseases ,MONOCLONAL antibodies ,MEDICAL specialties & specialists ,THERAPEUTICS ,NEUROLOGICAL disorders ,MULTIPLE sclerosis ,SPREADING cortical depression - Abstract
Over the last 30 years the role of monoclonal antibodies in therapeutics has increased enormously, revolutionizing treatment in most medical specialties, including neurology. Monoclonal antibodies are key therapeutic agents for several neurological conditions with diverse pathophysiological mechanisms, including multiple sclerosis, migraines and neuromuscular disease. In addition, a great number of monoclonal antibodies against several targets are being investigated for many more neurological diseases, which reflects our advances in understanding the pathogenesis of these diseases. Untangling the molecular mechanisms of disease allows monoclonal antibodies to block disease pathways accurately and efficiently with exceptional target specificity, minimizing non-specific effects. On the other hand, accumulating experience shows that monoclonal antibodies may carry class-specific and target-associated risks. This article provides an overview of different types of monoclonal antibodies and their characteristics and reviews monoclonal antibodies currently in use or under development for neurological disease. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
27. The prevalence and burden of medication overuse headache in Greece.
- Author
-
Constantinidis, Theodoros S., Arvaniti, Chryssa, Fakas, Nikolaos, Rudolf, Jobst, Kouremenos, Evangelos, Giannouli, Ermioni, and Mitsikostas, Dimos D.
- Subjects
- *
MEDICATION overuse headache , *TENSION headache , *MEDICATION abuse , *SOCIAL classes , *SOCIAL stratification - Abstract
Objective: To estimate the prevalence and burden of medication overuse headache in a representative sample of the Greek population, aged 18–70 years old. Methods: This is a cross-sectional descriptive observational study performed by quantitative computer-assisted telephone interviews, using a standardized 37-item questionnaire for headaches. The prevalence of medication overuse headache was estimated in the general population and compared within the groups formed by factors such as age, gender, diagnosis of headache type, prophylactic treatment used, geographical regions, social class, workdays lost and loss of productivity. Results: 1197 (12.0%) participants reported headaches affecting performance out of 10,008 interviewees. The estimated prevalence of medication overuse headache in the general population was 0.7% (95% CI: 0.5–0.9). The female to male ratio was 3.6:1. The proportion of medication overuse headache was largest in the 35–54 age group, followed by the over 55 group. The Aegean islands and Crete were the regions with the highest proportion of medication overuse headache. Among participants with headaches, the proportion of medication overuse headache was 5.8% (95% CI: 4.4%–7.1%); 6.3% (95% CI: 4.7%–7.9%) among females and 4.4% (95% CI: 2.2%–6.6%) among males. In the same headache group, the proportion of medication overuse headache by prophylactic treatment for headache was 19.0% (95% CI: 9.5%–29.1%) for recipients and 5.0% (95% CI: 3.8–6.3) for non-recipients. The mean absenteeism in people with medication overuse headache was 1.0 days/month (95% CI: 0.4–1.6) and the mean presenteeism 6.3 days/month (95% CI: 3.9–8.7). The social class stratification showed a significant effect between the medication overuse headache in the sample of the general population and the C2 class, corresponding to skilled manual labour (OR: 0.7, CI: 0.5–0.9). In people with chronic migraine, and chronic tension type headache, as differentiated by the 37-item questionnaire, the proportion of medication overuse headache in the headache group estimated to be 50.5% (95% CI: 40.8%–60.1%) and 45.9%, (95% CI: 29.9%–62.0%) respectively. The group of people with acute headache medication overuse fulfilling the rest of the diagnostic criteria for medication overuse headache, except from the number of headache days per month (≥15 days/month), had a prevalence of 2.0% (95% CI: 1.75–2.30) and a proportion of 17.0% (95% CI: 14.8%–19.1%) among people with headache. In the episodic types of headache, the proportion of acute headache medication overuse was higher in the subgroup of people with high frequency episodic migraine, 24.9% (95% CI: 18.8%–31.0%), while it was 10.8% (95% CI: 8.2%–13.5%), for the low frequency episodic migraine and 8.5% (95% CI: 5.5%–10.4%), for the episodic tension type headache. Conclusion: The prevalence of medication overuse headache in the general population in Greece and its proportion among the people with headache belongs to the lower part of the range of the reported literature, while the 3.6:1 female to male ratio is in agreement with it. In the same line, the impact of absenteeism and presenteeism on the workplace renders the condition alarming socio-economic health problem demanding immediate health policy planning. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
28. Visual snow: A systematic review and a case series.
- Author
-
Sampatakakis, Stefanos N, Lymperopoulos, Loukas, Mavridis, Theodoros, Karagiorgis, Georgios, Papadopoulos, Constantinos, Deligianni, Christina I, and Mitsikostas, Dimos D
- Subjects
- *
MIGRAINE aura , *NEUROLOGICAL disorders , *VISUAL fields , *SYMPTOMS , *EPIDEMIOLOGY - Abstract
Background: Visual Snow Syndrome is a recently recognized neurological condition presenting, continuous, tiny dots across the entire visual field, accompanied by nyctalopia, photophobia and palinopsia that persist for months. It may be part of migraine aura spectrum, yet its definition is still questionable. Diagnostic criteria for Visual Snow Syndrome are included in the supplemental material of ICHD-3. We aimed to summarize recent data to improve the understanding of Visual Snow Syndrome. Methods: After presenting four new cases, we conducted a PRISMA systematic search in PubMed/MEDLINE and Embase databases using the keyword "visual snow" with specific inclusion and exclusion criteria. Results: From the 855 articles identified 30 were included for the qualitative analysis. These reports covered five aspects related to Visual Snow Syndrome: epidemiology, clinical features, comorbidities, pathophysiology, and treatment. We found limited data concerning Visual Snow Syndrome's epidemiology (one study). Clinical presentation (22 articles) and the comorbidities (migraine with aura and tinnitus most often, five reports) are described in detail. The pathophysiology of Visual Snow Syndrome is only approached with hypotheses, but several neuroimaging studies have been identified (seven articles). Treatment is based on single case reports only. Conclusion: Data for Visual Snow Syndrome are few and not strong enough to support Visual Snow Syndrome as a medical identity. Further investigation is needed. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
29. Unmet Needs in Headache Management
- Author
-
Negro, Andrea, Martelletti, Paolo, Martelletti, Paolo, Series Editor, Mitsikostas, Dimos D., editor, and Benedetti, Fabrizio, editor
- Published
- 2019
- Full Text
- View/download PDF
30. Mechanisms of Pain and Headache
- Author
-
DaSilva, Alexandre F. M., DosSantos, Marcos Fabio, Martelletti, Paolo, Series Editor, Mitsikostas, Dimos D., editor, and Benedetti, Fabrizio, editor
- Published
- 2019
- Full Text
- View/download PDF
31. Informed Consent and the Ethics of Placebo-Based Interventions in Clinical Practice
- Author
-
Annoni, Marco, Miller, Franklin G., Martelletti, Paolo, Series Editor, Mitsikostas, Dimos D., editor, and Benedetti, Fabrizio, editor
- Published
- 2019
- Full Text
- View/download PDF
32. Diagnosis and management of migraine in ten steps.
- Author
-
Eigenbrodt, Anna K., Ashina, Håkan, Khan, Sabrina, Diener, Hans-Christoph, Mitsikostas, Dimos D., Sinclair, Alexandra J., Pozo-Rosich, Patricia, Martelletti, Paolo, Ducros, Anne, Lantéri-Minet, Michel, Braschinsky, Mark, del Rio, Margarita Sanchez, Daniel, Oved, Özge, Aynur, Mammadbayli, Ayten, Arons, Mihails, Skorobogatykh, Kirill, Romanenko, Vladimir, Terwindt, Gisela M., and Paemeleire, Koen
- Subjects
- *
PRIMARY headache disorders , *MIGRAINE , *EUROPEAN integration , *ADULTS , *TREATMENT failure , *PATIENT compliance - Abstract
Migraine is a disabling primary headache disorder that directly affects more than one billion people worldwide. Despite its widespread prevalence, migraine remains under-diagnosed and under-treated. To support clinical decision-making, we convened a European panel of experts to develop a ten-step approach to the diagnosis and management of migraine. Each step was established by expert consensus and supported by a review of current literature, and the Consensus Statement is endorsed by the European Headache Federation and the European Academy of Neurology. In this Consensus Statement, we introduce typical clinical features, diagnostic criteria and differential diagnoses of migraine. We then emphasize the value of patient centricity and patient education to ensure treatment adherence and satisfaction with care provision. Further, we outline best practices for acute and preventive treatment of migraine in various patient populations, including adults, children and adolescents, pregnant and breastfeeding women, and older people. In addition, we provide recommendations for evaluating treatment response and managing treatment failure. Lastly, we discuss the management of complications and comorbidities as well as the importance of planning long-term follow-up. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
33. A population-based survey for disabling headaches in Greece: Prevalence, burden and treatment preferences.
- Author
-
Constantinidis, Theodoros S, Arvaniti, Chryssa, Fakas, Nikolaos, Rudolf, Jobst, Kouremenos, Evangelos, Giannouli, Ermioni, and Mitsikostas, Dimos D
- Subjects
- *
HEADACHE , *PRIMARY headache disorders , *QUALITY of life , *ORAL medication , *ADULTS , *NEURAL stimulation - Abstract
Objective: To estimate the prevalence, burden and current treatment of disabling primary headaches in a large sample of the Greek population aged 18–70 years old. Methods: This is an observational descriptive study, with cross-sectional design performed by quantitative computer-assisted telephone interviews, using a validated 37-item questionnaire for headaches. The prevalence, burden, and current treatment of primary headaches (ICHD-3) were recorded along with participants' treatment preferences. Results: Out of 10,008 interviewed participants, 1197 (12.0%) reported headaches affecting performance. The annual prevalence of migraine was 8.1% (95% confidence interval, 7.6–8.7, corresponding to 0.6 million Greeks), of chronic migraine 1.0% (95% confidence interval, 0.8–1.2, corresponding to 0.1 million), and of tension-type headache 3.8% (95% confidence interval, 3.4–4.2, corresponding to 0.3 million). The participants with headaches reported 0.5 headache-induced lost workdays per month (corresponding to 5.8 million lost workdays annually) and reductions in performance on 2.8 workdays per month (corresponding to 30.9 million workdays annually). In all, 43.4% of headache participants felt bad/ashamed because of headaches and 21.9% sought professional treatment, most often from a private neurologist. 83.8% of headache participants had never taken pharmacological prophylaxis, and only 5.5% were currently under preventative treatment. For both prophylactic and acute treatment, headache participants prefer oral medication to injection or stimulation devices. Conclusion: More than 10% of the Greek adult population up to 70 years old experience disabling headaches, causing a dramatic work loss. More than 80% of these have never taken pharmacological prophylaxis. Thus, enriching the quality of life of people with headaches relies crucially on expanding awareness about headaches and their treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
34. Anti-CGRP monoclonal antibodies for migraine prevention: A systematic review and likelihood to help or harm analysis.
- Author
-
Drellia, Konstantina, Kokoti, Lili, Deligianni, Christina I, Papadopoulos, Dimitrios, and Mitsikostas, Dimos D
- Subjects
- *
MONOCLONAL antibodies , *CALCITONIN gene-related peptide , *MIGRAINE , *TERMINATION of treatment , *BOTULINUM A toxins - Abstract
Introduction and objective: Monoclonal antibodies targeting the calcitonin gene-related peptide pathway (anti-CGRP mAbs) have shown promising efficacy in randomised clinical trials for the prevention of episodic and chronic migraine, but no head-to-head comparisons with established treatments are available. We aimed to examine absolute differences in benefit-risk ratios between anti-CGRP mAbs, topiramate and propranolol for the prevention of episodic migraine and between anti-CGRP mAbs, topiramate and onabotulinumtoxinA for the prevention of chronic migraine using a likelihood to help versus harm analysis. Methods: The number of patients needed to be treated for a patient to achieve ≥ 50% reduction in migraine days (NNTB50%) was used as an effect size metric of efficacy. The number of patients needed to be treated for a patient to experience an adverse event that led to treatment discontinuation (NNTHD-AE) was used as a measure of risk. Likelihood to help versus harm values – which are the ratios of NNTH:NNTB – were calculated using data from phase 3 randomised clinical trials. Results: All agents tested were more likely to be beneficial than harmful (likelihood to help versus harm > 1) with the exception of topiramate at 200 mg per day for the prevention of episodic migraine. Anti-CGRP mAbs in all tested doses had higher LHH values than propranolol or topiramate for episodic migraine and onabotulinumtoxinA or topiramate for chronic migraine prevention. Fremanezumab had the highest LHH ratio in episodic migraine and galcanezumab in chronic migraine. Conclusion: This analysis showed that anti-CGRP mAbs exhibit a more favourable benefit-risk ratio than established treatments for episodic and chronic migraine. Head-to-head studies are needed to confirm these results. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
35. Migraine: integrated approaches to clinical management and emerging treatments.
- Author
-
Ashina, Messoud, Buse, Dawn C, Ashina, Håkan, Pozo-Rosich, Patricia, Peres, Mario F P, Lee, Mi Ji, Terwindt, Gisela M, Halker Singh, Rashmi, Tassorelli, Cristina, Do, Thien Phu, Mitsikostas, Dimos D, and Dodick, David W
- Subjects
- *
MIGRAINE , *NEUROLOGICAL disorders , *CONSTRUCTION planning - Abstract
Migraine is a highly disabling neurological disorder that directly affects more than 1 billion individuals worldwide. Available treatment options differ between countries and include acute, preventive, and non-pharmacological therapies. Because of major progress in the understanding of migraine pathogenesis, novel mechanism-based medications have emerged and expanded the armamentarium of treatments. We provide a comprehensive overview of the current standard of care that will enable informed clinical management. First, we discuss the efficacy, tolerability, and safety profile of various pharmacological therapies for acute and preventive treatment of migraine. Second, we review the current knowledge on non-pharmacological therapies, such as neuromodulation and biobehavioural approaches, which can be used for a multidisciplinary approach to clinical management. Third, we emphasise that any effective treatment strategy starts with building a therapeutic plan tailored to individual clinical characteristics, preferences, and needs. Finally, we explore the outlook of emerging mechanism-based treatments that could address unmet challenges in clinical management of migraine. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
36. Pharmacological Management of Migraine in Pregnancy
- Author
-
MacGregor, E. Anne, Martelletti, Paolo, Series editor, Jensen, Rigmor, Series editor, Mitsikostas, Dimos D., editor, and Paemeleire, Koen, editor
- Published
- 2016
- Full Text
- View/download PDF
37. Preventive Episodic Migraine Treatment
- Author
-
Ambrosini, Anna, Schoenen, Jean, Martelletti, Paolo, Series editor, Jensen, Rigmor, Series editor, Mitsikostas, Dimos D., editor, and Paemeleire, Koen, editor
- Published
- 2016
- Full Text
- View/download PDF
38. Review of Existing Guidelines
- Author
-
Evers, Stefan, Martelletti, Paolo, Series editor, Jensen, Rigmor, Series editor, Mitsikostas, Dimos D., editor, and Paemeleire, Koen, editor
- Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.